Mr. Ian McDonald reports

BRIGHT MINDS ANNOUNCES EFFECTIVE DATE OF SHARE CONSOLIDATION

Further to its news release on June 22, 2023, Bright Minds Biosciences Inc. will consolidate its common shares on a 1:5 basis.

The company's postconsolidation shares are expected to begin trading on the Canadian Securities Exchange and the Nasdaq Capital Market on July 14, 2023. The name of the company and trading symbol will remain the same after the consolidation. Following the consolidation, the company's Cusip number will be 10919W405 and the new ISIN will be CA10919W4056.

No fractional common shares will be issued upon the consolidation. In the event a holder of common shares would otherwise be entitled to receive a fractional common share in connection with the consolidation, the number of common shares to be received by such shareholder will be rounded down to the next whole number if that fractional common share is less than one-half of a common share, and will be rounded up to the next whole number of common shares if that fractional common share is equal to or greater than one-half of a common share.

Letters of transmittal with respect to the consolidation will be mailed to all registered shareholders of the company. All registered shareholders will be required to send their respective certificates representing the preconsolidation common shares along with a properly executed letter of transmittal to the company's transfer agent, Computershare Investor Services Inc., in accordance with the instructions provided in the letter of transmittal. Additional copies of the letter of transmittal can be obtained through Computershare at 1-800-564-6253. All shareholders who submit a duly completed letter of transmittal along with their respective preconsolidation common share certificate(s) to Computershare will receive a postconsolidation common share certificate or direct registration advice representing the postconsolidation common shares.

About Bright Minds Biosciences Inc.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD (posttraumatic stress disorder) and pain. The company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

We seek Safe Harbor.